alixorexton

all catalysts(0)

nothing on the calendar yet

News(3)

• Takeda approval ushers in new wave of sleep drugs
  An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.
  biopharma_dive · 5d ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 7d ago
• Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
  Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
  biopharma_dive · 1mo ago